He Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
He Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Pei Huang
2 shared publicationsChengfeng Yue
Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease and the Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publicationChengyuan Cai
1 shared publicationHonglei Hu
1 shared publicationJiachang Lin
Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease and the Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publicationJiacui Xie
Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease and the Fifth Affiliated Hospital, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by Tsinghua University Press in Nano Research
Dual-engine ferroptosis initiation via a hypoxia-responsive nanoplatform for colorectal cancer immunotherapy
Despite the promise of immunotherapy for colorectal cancer (CRC), efficacy is limited by an immunosuppressive microenvironment that resists single-modality interventions. Herein, we propose a dual‑engine ignition strategy for ferroptosis using a hypoxia‑responsive gadolinium‑coordination nanoplatform (PAD@CR) prepared via a one‑pot reaction among Gd³⁺, chlorin e6 (Ce6), retinoic acid (RA), and hypoxia‑sensitive PEG. This platform integrates two coordinated engines in a single system: Ce6 serves as the oxidative engine, generating ROS upon ultrasound activation, while RA acts as the brake‑release engine, inhibiting glycolysis to deplete NADPH and GSH, thereby dismantling the antioxidant defense. The convergence of these two orthogonal inputs overwhelms redox homeostasis and triggers immunogenic ferroptosis. The resulting DAMPs establish a positive feedback loop with α‑PD‑L1 therapy, promoting CD8⁺ T cell infiltration and long‑term immunological memory. Notably, IFN‑γ from activated T cells further suppresses GPX4, amplifying ferroptosis in a closed‑loop manner. In vivo, this dual‑engine ignition significantly inhibits tumor growth and extends survival without systemic toxicity. With scalable synthesis, integrated imaging‑therapy functions, and the ability to convert "cold" tumors into "hot" lesions, this nanoplatform offers a translatable strategy to overcome immunotherapy resistance in CRC.
- 6 November 2026
- Published by Tsinghua University Press in Nano Research
Open AccessDual-engine ferroptosis initiation via a hypoxia-responsive nanoplatform for colorectal cancer immunotherapy
Despite the promise of immunotherapy for colorectal cancer (CRC), efficacy is limited by an immunosuppressive microenvironment that resists single-modality interventions. Herein, we propose a dual‑engine ignition strategy for ferroptosis using a hypoxia‑responsive gadolinium‑coordination nanoplatform (PAD@CR) prepared via a one‑pot reaction among Gd³⁺, chlorin e6 (Ce6), retinoic acid (RA), and hypoxia‑sensitive PEG. This platform integrates two coordinated engines in a single system: Ce6 serves as the oxidative engine, generating ROS upon ultrasound activation, while RA acts as the brake‑release engine, inhibiting glycolysis to deplete NADPH and GSH, thereby dismantling the antioxidant defense. The convergence of these two orthogonal inputs overwhelms redox homeostasis and triggers immunogenic ferroptosis. The resulting DAMPs establish a positive feedback loop with α‑PD‑L1 therapy, promoting CD8⁺ T cell infiltration and long‑term immunological memory. Notably, IFN‑γ from activated T cells further suppresses GPX4, amplifying ferroptosis in a closed‑loop manner. In vivo, this dual‑engine ignition significantly inhibits tumor growth and extends survival without systemic toxicity. With scalable synthesis, integrated imaging‑therapy functions, and the ability to convert "cold" tumors into "hot" lesions, this nanoplatform offers a translatable strategy to overcome immunotherapy resistance in CRC.
- Open Access
- 25 November 2022
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (7) , 3153-3167
A redox-responsive self-assembling COA-4-arm PEG prodrug nanosystem for dual drug delivery suppresses cancer metastasis and drug resistance by downregulating hsp90 expression
- 25 November 2022
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (7) , 3153-3167
Open AccessA redox-responsive self-assembling COA-4-arm PEG prodrug nanosystem for dual drug delivery suppresses cancer metastasis and drug resistance by downregulating hsp90 expression